237 related articles for article (PubMed ID: 10898421)
1. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Montalescot G; Collet JP; Lison L; Choussat R; Ankri A; Vicaut E; Perlemuter K; Philippe F; Drobinski G; Thomas D
J Am Coll Cardiol; 2000 Jul; 36(1):110-4. PubMed ID: 10898421
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
Montalescot G; Bal-dit-Sollier C; Chibedi D; Collet JP; Soulat T; Dalby M; Choussat R; Cohen A; Slama M; Steg PG; Dubois-Randé JL; Metzger JP; Tarragano F; Guermonprez JL; Drouet L;
Am J Cardiol; 2003 Apr; 91(8):925-30. PubMed ID: 12686329
[TBL] [Abstract][Full Text] [Related]
3. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.
Montalescot G; Philippe F; Ankri A; Vicaut E; Bearez E; Poulard JE; Carrie D; Flammang D; Dutoit A; Carayon A; Jardel C; Chevrot M; Bastard JP; Bigonzi F; Thomas D
Circulation; 1998 Jul; 98(4):294-9. PubMed ID: 9711933
[TBL] [Abstract][Full Text] [Related]
4. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
[TBL] [Abstract][Full Text] [Related]
5. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulants in acute coronary syndromes.
Turpie AG
Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
[TBL] [Abstract][Full Text] [Related]
7. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
Antman EM; Cohen M; Radley D; McCabe C; Rush J; Premmereur J; Braunwald E
Circulation; 1999 Oct; 100(15):1602-8. PubMed ID: 10517730
[TBL] [Abstract][Full Text] [Related]
9. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
10. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
Fox KA
Am J Cardiol; 1999 Sep; 84(5A):26M-31M. PubMed ID: 10505540
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
[TBL] [Abstract][Full Text] [Related]
13. Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction.
Weitz JI; Bates SM
Arch Intern Med; 2000 Mar; 160(6):749-58. PubMed ID: 10737274
[TBL] [Abstract][Full Text] [Related]
14. [Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].
Averkov OV; Slavina NN; Gratsianskiĭ NA
Kardiologiia; 2003; 43(10):50-9. PubMed ID: 14593356
[TBL] [Abstract][Full Text] [Related]
15. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
Antman EM; McCabe CH; Braunwald E
Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024
[TBL] [Abstract][Full Text] [Related]
16. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.
Monrad ES
Am J Cardiol; 2000 Apr; 85(8A):2C-9C. PubMed ID: 10793174
[TBL] [Abstract][Full Text] [Related]
17. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Yusuf S
Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
[TBL] [Abstract][Full Text] [Related]
19. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction.
Hödl R; Huber K; Kraxner W; Nikfardjam M; Schumacher M; Fruhwald FM; Zorn G; Wonisch M; Klein W
Am J Cardiol; 2002 Mar; 89(5):589-92. PubMed ID: 11867046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
